Success Metrics

Clinical Success Rate
30.8%

Based on 4 completed trials

Completion Rate
31%(4/13)
Active Trials
0(0%)
Results Posted
200%(8 trials)
Terminated
9(69%)

Phase Distribution

Ph early_phase_1
1
8%
Ph phase_1
6
46%
Ph phase_2
4
31%
Ph not_applicable
2
15%

Phase Distribution

7

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution13 total trials
Early Phase 1First-in-human
1(7.7%)
Phase 1Safety & dosage
6(46.2%)
Phase 2Efficacy & side effects
4(30.8%)
N/ANon-phased studies
2(15.4%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

30.8%

4 of 13 finished

Non-Completion Rate

69.2%

9 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(4)
Terminated(9)

Detailed Status

Terminated9
Completed4

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
30.8%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (7.7%)
Phase 16 (46.2%)
Phase 24 (30.8%)
N/A2 (15.4%)

Trials by Status

completed431%
terminated969%

Recent Activity

0 active trials
Showing 5 of 13
completedearly_phase_1

Donor Stem Cell Transplantation for Congenital Immunodeficiencies

NCT00426517
terminatednot_applicable

Bone Marrow Transplantation, Hemoglobinopathies, SCALLOP

NCT00578344
terminatednot_applicable

Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO

NCT00578292
terminatedphase_1

Stem Cell Transplantation for Patients With Graft Failure Following an Allogeneic Transplant, Using Identical or Near Identical Donors and Less Toxic Conditioning With CAMPATH 1H

NCT00048399
terminatedphase_2

Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies

NCT00040469
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT00426517Early Phase 1

Donor Stem Cell Transplantation for Congenital Immunodeficiencies

Completed
NCT00578344Not Applicable

Bone Marrow Transplantation, Hemoglobinopathies, SCALLOP

Terminated
NCT00578292Not Applicable

Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO

Terminated
NCT00048399Phase 1

Stem Cell Transplantation for Patients With Graft Failure Following an Allogeneic Transplant, Using Identical or Near Identical Donors and Less Toxic Conditioning With CAMPATH 1H

Terminated
NCT00040469Phase 2

Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies

Terminated
NCT00048412Phase 1

Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H

Completed
NCT00282412Phase 1

Rheumatoid Arthritis:Tolerance Induction by Mixed Chimerism

Terminated
NCT00176865Phase 2

Stem Cell Transplant for Immunologic or Histiocytic Disorders

Completed
NCT00455312Phase 2

Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA

Completed
NCT00058825Phase 1

Stem Cell Transplant for Hematologic Diseases

Terminated
NCT00586274Phase 1

Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT

Terminated
NCT00579137Phase 1

Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders

Terminated
NCT00069992Phase 2

Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML

Terminated

All 13 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
13